L-Lysine monosalicylate | 57282-48-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: L-Lysine monosalicylate
• 英文别名: (2S)-2,6-diaminohexanoic acid;2-hydroxybenzoic acid
• CAS: 57282-48-1
• 化学式: C13H20N2O5
• 分子量: 284.31
• InChiKey: KZBKRARRXDZOII-ZSCHJXSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.62
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  147
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  L-赖氨酸 、 水杨酸 生成 L-Lysine monosalicylate
  参考文献：
  名称：

  PADR, Z.;GRIMOVA, J.;POHORSKY, J.;JEHLICKA, S.;TUMA, J.;VYHNANEK, K.

  摘要：

  DOI：

文献信息

• Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores
  申请人：Singh Chandra U.

  公开号：US20140134261A1

  公开（公告）日：2014-05-15

  The present invention relates to pharmaceutical compositions comprising ester(s) of capsaicin and at least one other agent selected from salicylates, menthol, boswellic acids, DMSO, methyl sulfonylmethane, NSAIDs, corticosteroids, emu oil, opioid agonists and antagonists, NMDA antagonists, tramadol, hyaluronic acid, α2δ ligands, santalol, santalyl acetate, amyris alcohol, amyris acetate, aloe vera gel and aloe vera juice, for improved therapeutic properties. Further, the present invention relates to pharmaceutical compositions comprising high concentrations of ester(s) of capsaicin. Further, the present invention relates to a method of relieving pain due to various diseases in subjects by administering the pharmaceutical compositions of the invention. Further, the present invention relates to methods of relieving fever blisters due to cold sores in subjects by administering the pharmaceutical compositions comprising an ester of capsaicin and one other agent selected from santalol, santalyl acetate, amyris alcohol and amyris acetate.

  本发明涉及含有辣椒素酯及至少一种来自水杨酸酯、薄荷脑、乳香酸、二甲基亚砜、甲基亚砜、非甾体抗炎药、皮质类固醇、鸸鹋油、阿片受体激动剂和拮抗剂、NMDA受体拮抗剂、曲马多、透明质酸、α2δ受体配体、檀香醇、檀香醋酸酯、白檀醇、白檀醋酸酯、芦荟凝胶和芦荟汁的药物组合物，用于改善治疗特性。此外，本发明涉及含有高浓度辣椒素酯的药物组合物。此外，本发明涉及通过给予本发明的药物组合物来减轻受试者因各种疾病而导致的疼痛的方法。此外，本发明涉及通过给予含有辣椒素酯及来自檀香醇、檀香醋酸酯、白檀醇和白檀醋酸酯中的一种的药物组合物来减轻受试者因感冒引起的发热疱疹的方法。
• Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
  申请人：Scherer Warren

  公开号：US10004734B2

  公开（公告）日：2018-06-26

  The present disclosure provides methods and compositions for treating or preventing erythema, including rebound erythema associated with the use of topical alpha-adrenergic agonists. In certain embodiments, an effective amount of a capsaicinoid, such as capsaicin or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject.

  本公开提供了治疗或预防红斑的方法和组合物，包括与使用局部α-肾上腺素能激动剂相关的反弹红斑。在某些实施方案中，向受试者施用有效量的辣椒素，如辣椒素或其药学上可接受的盐或衍生物。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods and compositions for treating conditions associated with an abnormal inflammatory response
  申请人：First Wave Bio, Inc.

  公开号：US10772854B2

  公开（公告）日：2020-09-15

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods of treatment
  申请人：First Wave Bio, Inc.

  公开号：US10980756B1

  公开（公告）日：2021-04-20

  This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity (e.g., a chemical purity of greater than about 99.0%) or a particular particle size (e.g., a particular particle size distribution and/or a particular particle size range and/or a specific surface area range). In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for administration to the GI tract (e.g., orally or rectally such as via enema)).

  本公开的化合物和组合物适用于治疗有需要的受试者的冠状病毒感染的方法（例如，适用于治疗COVID-19的方法）。这些方法包括向受试者施用烟酰胺化合物（或其药学上可接受的盐和/或共晶体，例如烟酰胺）。在一些实施方案中，烟酰胺化合物具有一种或多种特性，包括但不限于：特定的纯度（例如化学纯度大于约99.0%）或特定的粒度（例如特定的粒度分布和/或特定的粒度范围和/或比表面积范围）。在一个方面，本文所述的烟酰胺化合物（如烟酰胺）可以构成组合物、剂型（如单位剂型）等的一部分，适合呼吸道给药（如通过吸入和/或鼻内给药）。在另一方面，本文所述的烟酰胺化合物（如烟酰胺）可构成组合物、剂型（如单位剂型）等的一部分，适合于消化道给药（如口服或直肠给药，如通过灌肠））。